Exit / M&A
Prescient Therapeutics bringing new ‘basket’ approach to cancer trials
Profile of Australian cancer drug developer Prescient Therapeutics, whose basket-trial strategy echoes Loxo Oncology, acquired earlier in 2019 for US$8 billion.